• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.柳氮磺胺吡啶及其代谢产物的循环水平及其与该药物在溃疡性结肠炎中临床疗效的关系。
Gut. 1980 Aug;21(8):706-10. doi: 10.1136/gut.21.8.706.
2
Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.柳氮磺胺吡啶在溃疡性结肠炎治疗中代谢情况的进一步研究。
Br Med J. 1977 Oct 22;2(6094):1057-9. doi: 10.1136/bmj.2.6094.1057.
3
Sulphasalazine treatment during breast feeding.
Scand J Gastroenterol. 1979;14(7):869-71. doi: 10.3109/00365527909181418.
4
[Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment].[儿童溃疡性结肠炎。治疗期间柳氮磺胺吡啶和磺胺吡啶的水平]
Acta Gastroenterol Latinoam. 1988;18(2):107-13.
5
A comparison of serum concentrations of sulphasalazine and some of its metabolites after therapy by the oral or rectal route.口服或直肠给药治疗后柳氮磺胺吡啶及其某些代谢产物血清浓度的比较。
Pharmatherapeutica. 1984;3(8):551-5.
6
[Determination of sulfapyridine levels in serum--a possibility for the control of dose related therapy with sulfasalazine].[血清中磺胺吡啶水平的测定——控制柳氮磺胺吡啶剂量相关治疗的一种可能性]
Dtsch Z Verdau Stoffwechselkr. 1984;44(6):282-8.
7
[Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration].
Gastroenterol J. 1990;49(4):160-4.
8
Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?艾莎可在维持克罗恩病和溃疡性结肠炎缓解方面与柳氮磺胺吡啶一样有效吗？
Postgrad Med J. 1992 Mar;68(797):189-91. doi: 10.1136/pgmj.68.797.189.
9
Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy.柳氮磺胺吡啶治疗类风湿关节炎：剂量及血清水平与疗效的关系
Br J Rheumatol. 1985 Aug;24(3):269-76. doi: 10.1093/rheumatology/24.3.269.
10
Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation.
Acta Paediatr Scand. 1987 Jan;76(1):137-42. doi: 10.1111/j.1651-2227.1987.tb10430.x.

引用本文的文献

1
Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease.
Dig Dis Sci. 1995 Dec;40(12):2641-6. doi: 10.1007/BF02220454.
2
Kinetics of 5-aminosalicylic acid after jejunal instillation in man.人空肠滴注5-氨基水杨酸后的动力学
Br J Clin Pharmacol. 1983 Dec;16(6):738-40. doi: 10.1111/j.1365-2125.1983.tb02254.x.
3
The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.乙酰化表型对柳氮磺胺吡啶在人体内代谢的影响。
J Med Genet. 1983 Feb;20(1):30-6. doi: 10.1136/jmg.20.1.30.
4
Effects of ischaemic heart disease, Crohn's disease and antimicrobial therapy on the pharmacokinetics of sulphinpyrazone.缺血性心脏病、克罗恩病及抗菌治疗对磺吡酮药代动力学的影响。
Clin Pharmacokinet. 1986 Sep-Oct;11(5):402-10. doi: 10.2165/00003088-198611050-00005.
5
Absorption of 5-aminosalicylic acid from colon and rectum.5-氨基水杨酸在结肠和直肠的吸收。
Br J Clin Pharmacol. 1988 Feb;25(2):269-72. doi: 10.1111/j.1365-2125.1988.tb03301.x.
6
Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis.乙酰化表型对柳氮磺胺吡啶治疗类风湿关节炎疗效和毒性的影响。
Ann Rheum Dis. 1985 Dec;44(12):831-7. doi: 10.1136/ard.44.12.831.
7
Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.柳氮磺胺吡啶、其代谢产物及其他5-氨基水杨酸前体药物的临床药代动力学。
Clin Pharmacokinet. 1985 Jul-Aug;10(4):285-302. doi: 10.2165/00003088-198510040-00001.
8
Inflammatory intermediaries in inflammatory bowel disease.炎症性肠病中的炎症介质
Int J Colorectal Dis. 1989;4(2):75-90. doi: 10.1007/BF01646865.
9
Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).用于治疗胃肠道疾病的药物的临床药代动力学（第二部分）。
Clin Pharmacokinet. 1990 Aug;19(2):94-125. doi: 10.2165/00003088-199019020-00002.
10
Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease.柳氮磺胺吡啶在类风湿关节炎和炎性肠病中的单剂量药代动力学比较。
Ann Rheum Dis. 1990 Aug;49(8):587-90. doi: 10.1136/ard.49.8.587.

本文引用的文献

1
Biopsy studies in ulcerative colitis.溃疡性结肠炎的活检研究。
Br Med J. 1956 Jun 9;1(4979):1315-8. doi: 10.1136/bmj.1.4979.1315.
2
An improved and simplified method of detecting the acetylator phenotype.一种检测乙酰化酶表型的改良简化方法。
J Med Genet. 1969 Dec;6(4):405-7. doi: 10.1136/jmg.6.4.405.
3
Absorption, metabolism, and excretion of salicylazosulfapyridine in man.柳氮磺胺吡啶在人体中的吸收、代谢及排泄
Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539-51. doi: 10.1002/cpt1972134539.
4
The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.柳氮磺胺吡啶在溃疡性结肠炎中的代谢。I. 住院患者中代谢产物与治疗反应的关系
Gut. 1973 Aug;14(8):631-41. doi: 10.1136/gut.14.8.631.
5
Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine.柳氮磺胺吡啶给药后血清和尿液中游离及乙酰化5-氨基水杨酸的测定
Acta Pharm Suec. 1973 May;10(2):153-5.
6
Determination of salicylazosulphapyridine in biological materials.
Acta Pharm Suec. 1973 May;10(2):107-10.
7
Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.柳氮磺胺吡啶给药后生物材料中磺胺吡啶及其代谢产物的测定
Acta Pharm Suec. 1973 Mar;10(1):87-92.

柳氮磺胺吡啶及其代谢产物的循环水平及其与该药物在溃疡性结肠炎中临床疗效的关系。

Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.

作者信息

Azad Khan A K, Truelove S C

出版信息

Gut. 1980 Aug;21(8):706-10. doi: 10.1136/gut.21.8.706.

DOI:10.1136/gut.21.8.706
PMID:6107264
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1419120/
Abstract

One hundred and eighty-five patients with ulcerative colitis have been studied serially while receiving regular maintenance treatment with sulphasalazine (SASP) in a dose of 0.5 g four times daily. The circulating levels of the drug and its principal metabolites during remission do not influence the liability to relapse. When relapse does occur, the circulating level of sulphapyridine falls and remains depressed until remission occurs. This fall during a relapse is most pronounced when the patient suffers from universal colitis and is least marked in cases of distal colitis.

摘要

对185例溃疡性结肠炎患者进行了连续研究，这些患者在接受柳氮磺胺吡啶（SASP）常规维持治疗，剂量为每日4次，每次0.5克。缓解期药物及其主要代谢产物的循环水平不会影响复发倾向。当复发确实发生时，磺胺吡啶的循环水平下降并一直保持在低水平，直到缓解出现。复发期间的这种下降在全结肠炎患者中最为明显，在远端结肠炎患者中最不明显。